Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06686940
Starting soon Observational

Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden

NCT06686940 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Observational
Started
2024-12-30
Last updated
2024-11-13

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

intervention group

intervention group: The monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.

Study summary

The purpose of this study is to evaluate the monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Atrial fibrillation patients diagnosed by electrocardiogram 2. Willing to use long-range electrocardiogram monitoring equipment Exclusion Criteria: 1.Patients who are allergic to electronic devices or unable to wear watches

Primary outcome measure(s)

  • Primary outcome — December 30, 2024 to Decemberr 30, 2034
    all-cause death, cardiovascular death, myocardial infarction, heart failure, stroke, peripheral vascular disease, recurrence of atrial fibrillation diagnosed by electrocardiogram, palpitations symptoms

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital Beijing Beijing Municipality

More Beijing Anzhen Hospital trials in China

Safety and Efficacy of a Novel Composite-Tip Guiding Catheter in Transcarotid Artery Stenting Via Transradial Access Recruiting
A Multicenter Study of Artificial Intelligence Model for Fetal Congenital Heart Disease Starting soon
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF) Recruiting
Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD) Starting soon
Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention Recruiting

Other trials for the same condition

Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF) Recruiting
Nudging for Anticoagulation Adherence in Atrial Fibrillation Starting soon
PulseMagic™ TrueForce™ PAF NMPA Study Starting soon
Photoplethysmography (PPG) Algorithm with Smartwatch in Evaluation of Atrial Fibrillation Burden After Catheter Ablation Starting soon
Testing the Performance of Smartphones and Their Accessories in Detecting Irregularly Irregular Heart Rhythm Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06686940 on ClinicalTrials.gov ↗ ← All trials in China